611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO, CA
Earnings Release
Shareholder votes
Reports First Quarter 2025 Financial Results and Recent Highlights
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights
Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
Reports Third Quarter 2024 Financial Results and Recent Highlights
Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer
Q2
Q1
FY 2023
Q3
S-3ASR
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
S-1
Direct Registration System
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership